The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ACAA2 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ACAA2 mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ACAA2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ACHE mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of ACHE protein ACHE protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP3 protein]; ACHE protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP9 protein] ACHE protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACSL4 protein]; ferrostatin-1 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACSL4 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACTR1A mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ACTR1A mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ACTR1A mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACTR1A mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACTR1A mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADCY7 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADCY7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ADCY7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADCY7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADCY7 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ADGRL1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADGRL1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADGRL1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ADGRL1 mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ADGRL1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADNP mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADNP mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADNP mRNA]
amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein]; Vincamine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IBA1 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IBA1 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AKR1A1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of AKR1A1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of AKR1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AKR1A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AKR1A1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of AKT1 protein AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of AKT1 protein]; bis(3)-cognitin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of AKT1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ALDH1A1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ALDH1A1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ALDH1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ALDH1A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ALDH1A1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of APEX1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of APEX1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of APEX1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of APEX1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of API5 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of API5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of API5 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ARF1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ARF1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF3 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ARF3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ASPM mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ASPM mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ASPM mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0A4 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ATP6V0A4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0A4 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0C mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATP6V0C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0C mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V1B2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATP6V1B2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V1B2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP9A mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ATP9A mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP9A mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATRN mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATRN mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATRN mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATRN mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATRN mRNA]
2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAD protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAP1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BAP1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAP1 mRNA]
[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BAX mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BAX protein; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BAX mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BAX protein]; ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]; mangiferin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]
2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2 mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2 protein; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2 mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2 protein]; ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; mangiferin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2L10 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2L10 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2L10 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BDNF mRNA geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF mRNA]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]; MIR210 mRNA affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]; salvianolic acid B inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BNIP3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BNIP3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BNIP3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BNIP3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BNIP3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1R mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of C1R mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of C1R mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1R mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1R mRNA]
Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1S mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1S mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CALM1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CALM1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CALM1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CALM1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CALM1 mRNA]
1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CASP1 mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CASP1 mRNA; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP1 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP1 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP12 mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP12 protein TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP12 protein] [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP12 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP12 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of and results in increased activity of CASP3 protein; 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of and results in increased activity of CASP3 protein]; 6,7-dihydroxyflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of CASP3 protein]; [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein]; ACHE protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP9 mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP9 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of and results in increased activity of CASP9 protein; 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of and results in increased activity of CASP9 protein]; [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CASP9 mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 protein; ACHE protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP9 protein]; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP9 mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP9 mRNA]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CAT protein]; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased activity of CAT protein; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased activity of CAT protein]; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CAT protein] Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]; ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CBX5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CBX5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CBX5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CBX5 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 protein (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) trifluoroethylamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 mRNA]; 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CCL2 mRNA]; 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CCL2 mRNA; Dimethyl Fumarate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 mRNA]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNB1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNB1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCND2 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCND2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCND2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNF mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CCNF mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNF mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNL2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNL2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNL2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNL2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCR2 protein TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCR2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CD151 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CD151 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CD151 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD44 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CD44 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD44 mRNA]
(2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) trifluoroethylamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD68 mRNA]; 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD68 mRNA]; Dimethyl Fumarate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD68 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CD9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD9 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CDC42 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CDC42 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CDC42 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CDH11 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CDH11 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CDH11 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CDH11 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CETN3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CETN3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CETN3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CETN3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CETN3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CIB1 mRNA CIB1 gene mutant form results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CIB1 mRNA; CIB1 gene mutant form promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of MAP3K5 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CIB1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CKMT1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CKMT1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CKMT1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CKMT1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLCA2 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CLCA2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLCA2 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CLSTN1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CLSTN1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLSTN1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLSTN1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CNN2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CNN2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CNN2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CNN2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CNN2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR1 protein AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR1 mRNA]; AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR2 protein AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR2 mRNA]; AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR2 protein]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL1A1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL1A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL1A1 mRNA] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COL1A1 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL6A1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL6A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL6A1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COQ8A mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COQ8A mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX5A protein Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX5A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX5A protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7A2L mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7A2L mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of COX7A2L mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7A2L mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7A2L mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7C mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7C mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7C mRNA]
CSF3 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MTA1 protein]; CSF3 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CST3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CST3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CST3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CST3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CST3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSB mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSB mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSB mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSB mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSB mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSL mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSL mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CTSL mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSL mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSL mRNA]
[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CYC1 protein; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CYC1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP11A1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CYP11A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP11A1 mRNA]
CYP2D6 protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]]; Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]]; Ketoconazole promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]; Ketoconazole promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DCXR mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DCXR mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DCXR mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein] TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein] guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DLST protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DLST protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJA1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJA1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJA1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJA1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJA1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJB9 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of DNAJB9 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJB9 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJB9 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJB9 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DPP4 mRNA MPTP increases activity of Dpp4 protein in the frontal cortex and nucleus accumbens [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DPP4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DPP4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DPP4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DPP4 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DPYSL2 protein Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DPYSL2 protein]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ECM1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ECM1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ECM1 mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ECM1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EEF1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EEF1A1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EEF2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EEF2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EEF2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EFNA1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EFNA1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EFNA1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EFNB3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EFNB3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EFNB3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EFNB3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EFNB3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EGR1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EGR1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EGR1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF2B4 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF2B4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF2B4 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF4E mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF4E mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF4E mRNA]; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF4E mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EIF5 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EIF5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EIF5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EIF5 mRNA]
[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO1 mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ENO1 protein [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ENO1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ENO1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO1 mRNA]; Minocycline inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ENO1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO1 mRNA]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ENO1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ENO2 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO2 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 protein TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 protein] [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERN1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERN1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 mRNA]; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERP44 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERP44 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ERP44 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERP44 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERP44 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ETFA mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ETFA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ETFA mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EZR mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EZR mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EZR mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EZR mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of FBXL12 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of FBXL12 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FBXL12 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FBXL12 mRNA]
FMC1 gene mutant form results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FMC1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FMC1 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of FOSB protein; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of FOSB protein alternative form
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FTH1 protein 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FTH1 protein]; ferrostatin-1 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FTH1 protein]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of FYN mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FYN mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GAB1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GAB1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GALE mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GALE mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GALE mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA]; [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAPDH mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAPDH mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAPDH mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAPDH mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAPDH mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GATA6 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GATA6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GATA6 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GCLC mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GCLC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GCLC mRNA]
[GDNF protein co-treated with Cyclic AMP] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine GDNF protein promotes the reaction [Sodium Benzoate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF mRNA]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF protein]; Sodium Benzoate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF protein
[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of GFAP protein; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GFAP protein; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; Dieldrin promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GFAP protein]; Vincamine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; Zonisamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GHITM mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GHITM mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GHITM mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GHITM mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GHITM mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GMFB mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GMFB mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GMFB mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GMFB mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GMFB mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GNAI2 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GNAI2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GNAI2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GOLT1B mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GOLT1B mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GOLT1B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GOLT1B mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GOLT1B mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPRC5C mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPRC5C mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPRC5C mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPX3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPX3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPX3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPX3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GPX4 protein 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GPX4 protein]; ferrostatin-1 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GPX4 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GRID2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]; cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein] [mithramycin A co-treated with astaxanthine] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]; astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA]; astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]; astaxanthine promotes the reaction [mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA]]; astaxanthine promotes the reaction [mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]]; mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA]; mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]; mithramycin A promotes the reaction [astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA]]; mithramycin A promotes the reaction [astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of GSK3B protein 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of GSK3B protein]; bis(3)-cognitin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of GSK3B protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GSTA4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GSTA4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GSTA4 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GSTA4 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GSTA4 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HBA-A1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HBA-A1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HBA-A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HBA-A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HBA-A1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HELLS mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HELLS mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HELLS mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HELLS mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HELLS mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HIF1A mRNA; [Clioquinol co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HIF1A protein [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolite] affects the localization of HIF1A protein; [salicylaldehyde isonicotinoyl hydrazone co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolite] affects the localization of HIF1A protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HINT1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HINT1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HINT1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HINT1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HINT1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HIPK1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HIPK1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HIPK1 mRNA]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HMOX1 mRNA; [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HMOX1 protein; [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HMOX1 protein]; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; Vincamine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HMOX1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HNRNPC mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HNRNPC mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HNRNPC mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HNRNPC mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HNRNPC mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HRAS mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HRAS mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HRAS mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HRAS mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HRAS mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSP90AA1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HSP90AA1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HSP90AA1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSP90AA1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSP90AA1 mRNA]
TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPA5 protein] Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPA5 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPE1 mRNA Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPE1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPE1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ICAM1 protein TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ICAM1 protein]
Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IDH3A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IDH3A protein]
4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 mRNA]]; 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]]; 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 mRNA]]; 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]]; H 1356 inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 mRNA]]; H 1356 inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]]; H 1356 inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 mRNA]]; H 1356 inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]]; IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 mRNA]; IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 mRNA]; IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IGF1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL17A protein IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IGF1 protein]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL1A mRNA 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of IL1A mRNA]; 1,1-bis(3'-indolyl)-1-(p-anisyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of IL1A mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of IL1A mRNA guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL1A mRNA]
Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]] amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; salvianolic acid B inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; Vincamine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; Vincamine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL2 protein TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4 protein TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4RA mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IL4RA mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of IL4RA mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4RA mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4RA mRNA]
IL6 protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 protein]; HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 protein]; Vincamine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA]; Vincamine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL6 mRNA guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL6 mRNA]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL6 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IRAK1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRAK1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRAK1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IRAK1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IRAK1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRX3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRX3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IRX3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IRX3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ITM2B mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ITM2B mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ITM2B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ITM2B mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ITM2B mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of JMJD6 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of JMJD6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of JMJD6 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of KAT6B mRNA; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KAT6B mRNA]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KEAP1 protein]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KEAP1 protein]; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KEAP1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF3B mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KIF3B mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of KIF3B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF3B mRNA]; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF3B mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KLF4 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KLF4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KLF4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KLF4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KLF4 mRNA]
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]; TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]; TIGAR protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LPAR4 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of LPAR4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of LPAR4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LPAR4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LPAR4 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of LRRK2 protein HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of LRRK2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOA mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MAOA mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAOA mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOA mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOA mRNA]
[MAOB protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of 1-Methyl-4-phenylpyridinium; [MAOB protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased chemical synthesis of 1-Methyl-4-phenylpyridinium; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOB protein]; Zonisamide inhibits the reaction [[MAOB protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased chemical synthesis of 1-Methyl-4-phenylpyridinium] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of MAOB protein 5-nitroindazole inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; 9-mono-N'-methylnorharman inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; Methylene Blue inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; norharman inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; Vitamin K 3 inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MAP2K7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAP2K7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP2K7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP2K7 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP3K12 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAP3K12 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP3K12 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of MAP3K5 protein CIB1 gene mutant form promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of MAP3K5 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAPK1 mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of MAPK1 protein U 0126 promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of MAPK1 protein] [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAPK1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAPK1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of MAPK3 protein U 0126 promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of MAPK3 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MC2R mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MC2R mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MC2R mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ME1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ME1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ME1 mRNA]
MIR210 mRNA affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MIR210 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MMP7 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MMP7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MMP7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MMP7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MMP7 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL10 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MRPL10 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL10 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL20 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL20 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL20 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL20 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL20 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MRPL9 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL9 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL9 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MRPL9 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MRPL9 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MT2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MT2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MTA1 protein CSF3 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MTA1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTCH1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTCH1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MTCH1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTCH1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTCH1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTF2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTF2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTF2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTF2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFB5 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NDUFB5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NDUFB5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFB5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFB5 mRNA]
NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFS4 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NDUFS4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFS4 mRNA]
NFE2L2 gene mutant form results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the expression of MIR380 mRNA]; NFE2L2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MIR138-1 mRNA]; NFE2L2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MIR674 mRNA]; salvianolic acid B inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; Vincamine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of and results in increased phosphorylation of NFKBIA protein; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of and results in increased phosphorylation of NFKBIA protein]; Vincamine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of NFKBIA protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NGB mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NGB mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NGB mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 protein baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 protein]; HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS1 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NOS1 protein NOS1 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased ribosylation of Adenosine Diphosphate Ribose]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of NOS2 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 mRNA]]; 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]]; [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; H 1356 inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 mRNA]]; H 1356 inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]]; IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 mRNA]; IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 mRNA]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of NOS2 protein]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NPL mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NPL mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NPL mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NPL mRNA]
1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] affects the localization of and results in decreased expression of NR4A2 protein]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] affects the localization of and results in decreased expression of NR4A2 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NSF mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NSF mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NSF mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NSF mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NSF mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NSF mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NUPR1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NUPR1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NUPR1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NUPR1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NUPR1 mRNA]
[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of OCLN protein; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of OCLN protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of OCLN protein
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of P3H3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of P3H3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of P3H3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of P3H3 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PAK2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PAK2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PAK2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PAK2 mRNA]
PARK7 protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PARK7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PARK7 mRNA]; PARK7 protein inhibits the reaction [PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
[PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of 3,4-Dihydroxyphenylacetic Acid; [PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of Dopamine; [PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of Homovanillic Acid
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDIA6 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PDIA6 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PDIA6 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDIA6 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDIA6 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PFDN1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PFDN1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PFDN1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PFDN1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PFDN1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHB1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHB1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHB1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHB1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHTF1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PHTF1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHTF1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHTF1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHTF1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIDD1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIDD1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIDD1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIDD1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIDD1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIGC mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIGC mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIGC mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIGC mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIGC mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PIN1 mRNA; juglone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 mRNA]; juglone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 mRNA]
PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PINK1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PINK1 protein AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PINK1 mRNA]; AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PINK1 protein]; PARK7 protein inhibits the reaction [PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; PRKN protein inhibits the reaction [PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIP5K1C mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIP5K1C mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIP5K1C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIP5K1C mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIP5K1C mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PLAA mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PLAA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PLAA mRNA]
PNOC affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PNOC protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PNPLA8 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PNPLA8 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PNPLA8 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PNPLA8 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PNPLA8 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPARGC1A mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPARGC1A mRNA alternative form
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPM1B mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PPM1B mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PPM1B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPM1B mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPM1B mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PPP2R3C mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PPP2R3C mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PPP2R3C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PPP2R3C mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PPP2R3C mRNA]
Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX2 protein]; Minocycline inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX2 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRDX3 mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX3 protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PRDX3 mRNA; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX3 protein]; Minocycline inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRDX3 mRNA]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX3 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKAB1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PRKAB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKAB1 mRNA]
PRKN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH] AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKN mRNA]; AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKN protein]; PRKN protein inhibits the reaction [PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] PRKN protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKN mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKN protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRKN mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRKN protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC2 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC5 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC5 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PSMG2 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMG2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PSMG2 mRNA]
guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein] 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 mRNA]]; 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]; H 1356 inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 mRNA]]; H 1356 inhibits the reaction [IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]]; IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 mRNA]; IGF1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 mRNA] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PYCARD mRNA; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD protein]; HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RAB2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAB2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RAB7 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RAB7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAB7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RAB7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RAB7 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RAD50 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD50 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD50 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD50 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RASA3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RASA3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RASA3 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RASA3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RASA3 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RBBP4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RBBP4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RBBP4 mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RBBP4 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RBBP5 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RBBP5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RBBP5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RBBP5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RBBP5 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of RELA protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of RELA protein baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of RELA protein]; Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RELA protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of RELA protein]; Vincamine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of RELA protein] guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of RELA protein]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of RELA protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RGS2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RGS2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RGS2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RGS2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RGS2 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL26 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL26 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RPL26 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RPL26 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RPL5 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RPL5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RPL5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RPL5 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RSPO3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RSPO3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RSPO3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RSPO3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RSPO3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SAP18 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SAP18 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SAP18 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SENP6 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SENP6 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SENP6 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SENP6 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SENP6 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SEPTIN7 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SEPTIN7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SEPTIN7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SEPTIN7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SEPTIN7 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SFPQ mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SFPQ mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SFPQ mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SFPQ mRNA]
[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC18A2 protein; Estradiol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of SLC18A2 protein]; Estradiol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein]; Estrone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein] SLC18A2 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of SLC1A1 protein Acetylcysteine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of SLC1A1 protein]; Acetylcysteine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the metabolism of SLC1A1 protein]
[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC2A1 protein; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC2A1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC40A1 protein 3,4-dihydroxybenzoate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC40A1 protein]
1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC6A3 protein]; 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC6A3 protein]; 1,1-bis(3'-indolyl)-1-(p-anisyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC6A3 protein]; 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC6A3 protein; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC6A3 protein; Estradiol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of SLC6A3 protein]; Estrone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of SLC6A3 protein]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]; Glyburide promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]; SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SLC6A3 protein]; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC6A3 protein]; vanoxerine inhibits the reaction [SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMAD1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMAD1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMAD1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMAD1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMAD1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SMAD3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMAD3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SMAD3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SMAD3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SMAD3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMPD3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMPD3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SMPD3 mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMPD3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMPD3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein binds to SNCA protein]; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB3A protein]; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB5A protein]; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB8A protein]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; Dieldrin promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; ferrostatin-1 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein U 0126 promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of and affects the localization of SNCA protein alternative form; GPX1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form]; U 0126 promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form] SNCA affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SNCA protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCG mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SNCG mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCG mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SOD2 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SOD2 protein [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SOD2 protein; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SOD2 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SOD2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA SP1 affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of and affects the localization of SP1 protein; [mithramycin A co-treated with astaxanthine] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of and affects the localization of SP1 protein]; astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA]; astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 protein]; astaxanthine promotes the reaction [mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA]]; astaxanthine promotes the reaction [mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 protein]]; mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA]; mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 protein]; mithramycin A promotes the reaction [astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA]]; mithramycin A promotes the reaction [astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 protein]]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SRP9 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SRP9 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SRP9 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SRP9 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SRP9 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STIP1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of STIP1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of STIP1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STIP1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STIP1 mRNA]
Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of STMN1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of STMN1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STX4A mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of STX4A mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of STX4A mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STX4A mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STX4A mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SYNGR2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SYNGR2 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SYT4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SYT4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SYT4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SYT4 mRNA] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SYT4 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TFRC mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TFRC mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TFRC mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TFRC mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TFRC mRNA]
TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFB1 protein] [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Cromolyn Sodium] results in increased secretion of TGFB1 protein; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with masitinib co-treated with Cromolyn Sodium] results in increased secretion of TGFB1 protein; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with masitinib] results in increased secretion of TGFB1 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFB1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFB1 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFBR1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFBR1 protein
TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCR2 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ICAM1 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL2 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KIT protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PECAM1 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SLC6A3 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFB1 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGM2 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VCAM1 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of TGM2 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of TH protein]; 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of TH protein]; 1,1-bis(3'-indolyl)-1-(p-anisyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of TH protein]; 1-(3-(2-(1-benzothiophen-5-yl) ethoxy) propyl)-3-azetidinol maleate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [[Clozapine results in increased activity of TH protein] which results in increased metabolism of Dopamine]; 3-Hydroxybutyric Acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of TH protein; [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TH mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TH mRNA; [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; [Zonisamide co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] affects the activity of TH protein; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TH protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; CSF3 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; ferrostatin-1 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; GDNF protein promotes the reaction [Sodium Benzoate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Glyburide promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; HOTAIR affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; juglone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]]; Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Sodium Benzoate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Zonisamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] PRKN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]; TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]; TIGAR protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIGAR protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TIMP3 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIMP3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TIMP3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIRAP mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIRAP mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIRAP mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIRAP mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIRAP mRNA]
[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TJP1 protein; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TJP1 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TJP1 protein
1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of TLR4 mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of TLR4 mRNA; Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TLR4 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) trifluoroethylamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of TNF mRNA; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; Dimethyl Fumarate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; Melatonin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; salvianolic acid B inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; sophoricoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; Vincamine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; Vincamine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein] Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TNK2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TNK2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNK2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNK2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPH2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPH2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPH2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPH2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPP2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPP2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPP2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPP2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPP2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRAF2 protein TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRAF2 protein]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TSC22D1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TSC22D1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TSC22D1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TSC22D1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TUBA1A protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TUBA1A protein]
TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP12 protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPA5 protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRAF2 protein] Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TXN1 protein] TXN protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TXN protein; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TXN1 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UBB mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBB mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBB mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UBB mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UBB mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBC mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBC mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBC mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBC mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBC mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UBE2D2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UBE2D2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBE2D2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBE2D2 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UCHL1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UCHL1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 mRNA] UCHL1 protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UCHL1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UCHL1 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UROS mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UROS mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UROS mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UROS mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UROS mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VCAM1 protein TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VCAM1 protein]
VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of NOS2 protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of VPS28 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of VPS28 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of VPS28 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VPS41 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of VPS41 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of VPS41 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VPS41 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VPS41 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of WBP4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of WBP4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of WBP4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of WBP4 mRNA]
U 0126 inhibits the reaction [Arecoline results in increased expression of ACTA2 protein] Arecoline results in increased expression of ACTA2 mRNA; Arecoline results in increased expression of ACTA2 protein
[arecoline hydrobromide results in increased abundance of Arecoline] inhibits the reaction [AKT activator SC79 results in decreased phosphorylation of AKT1 protein]; [arecoline hydrobromide results in increased abundance of Arecoline] which results in decreased phosphorylation of AKT1 protein; PHLPP2 protein affects the reaction [[arecoline hydrobromide results in increased abundance of Arecoline] which results in decreased phosphorylation of AKT1 protein] Arecoline affects the phosphorylation of AKT1 protein
4-phenylbutyric acid inhibits the reaction [Arecoline results in increased expression of ATF6 protein]; Acetylcysteine inhibits the reaction [Arecoline results in increased expression of ATF6 protein] Arecoline results in increased expression of ATF6 mRNA; Arecoline results in increased expression of ATF6 protein
Arecoline results in increased cleavage of CASP12 protein 4-phenylbutyric acid inhibits the reaction [Arecoline results in increased cleavage of CASP12 protein]; Acetylcysteine inhibits the reaction [Arecoline results in increased cleavage of CASP12 protein]
Arecoline results in increased activity of CASP3 protein Arecoline results in increased cleavage of CASP3 protein 4-phenylbutyric acid inhibits the reaction [Arecoline results in increased cleavage of CASP3 protein]; Acetylcysteine inhibits the reaction [Arecoline results in increased cleavage of CASP3 protein]
Arecoline results in increased cleavage of CASP9 protein 4-phenylbutyric acid inhibits the reaction [Arecoline results in increased cleavage of CASP9 protein]; Acetylcysteine inhibits the reaction [Arecoline results in increased cleavage of CASP9 protein]
Arecoline results in increased expression of CCND1 mRNA; Arecoline results in increased expression of CCND1 protein [arecoline hydrobromide results in increased abundance of Arecoline] inhibits the reaction [AKT activator SC79 results in decreased expression of CCND1 protein]; [arecoline hydrobromide results in increased abundance of Arecoline] which results in decreased expression of CCND1 protein
[[Arecoline results in decreased expression of CDC25C] co-treated with [Arecoline results in increased expression of TP53]] results in decreased activity of CDK1 protein Arecoline results in decreased expression of CDC25C protein
Arecoline results in decreased activity of CDK1 protein [[Arecoline results in decreased expression of CDC25C] co-treated with [Arecoline results in increased expression of TP53]] results in decreased activity of CDK1 protein
Arecoline inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Arecoline inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
4-phenylbutyric acid inhibits the reaction [Arecoline results in increased phosphorylation of DDIT3 protein]; Acetylcysteine inhibits the reaction [Arecoline results in increased expression of DDIT3 protein] Arecoline results in increased expression of DDIT3 mRNA; Arecoline results in increased expression of DDIT3 protein
[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein; [helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the localization of EGFR protein modified form; helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein]
Arecoline results in increased phosphorylation of EIF2AK3 protein 4-phenylbutyric acid inhibits the reaction [Arecoline results in increased phosphorylation of EIF2AK3 protein]; Acetylcysteine inhibits the reaction [Arecoline results in increased phosphorylation of EIF2AK3 protein] Arecoline results in increased expression of EIF2AK3 mRNA
4-phenylbutyric acid inhibits the reaction [Arecoline results in increased phosphorylation of ERN1 protein]; Acetylcysteine inhibits the reaction [Arecoline results in increased phosphorylation of ERN1 protein] Arecoline results in increased expression of ERN1 mRNA
[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the expression of FOS protein; [helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the localization of FOS protein
4-phenylbutyric acid inhibits the reaction [Arecoline results in increased expression of HSPA5 protein]; Acetylcysteine inhibits the reaction [Arecoline results in increased expression of HSPA5 protein] Arecoline results in increased expression of HSPA5 mRNA; Arecoline results in increased expression of HSPA5 protein
Arecoline results in decreased secretion of IL6 protein Arecoline results in decreased expression of IL6 mRNA Arecoline results in increased expression of IL6 protein
[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the phosphorylation of MAPK1 protein; Dinoprostone affects the reaction [[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the phosphorylation of MAPK1 protein] Arecoline results in increased phosphorylation of MAPK1 protein U 0126 inhibits the reaction [Arecoline results in increased phosphorylation of MAPK1 protein]
[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the phosphorylation of MAPK3 protein; Dinoprostone affects the reaction [[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the phosphorylation of MAPK3 protein] Arecoline results in increased phosphorylation of MAPK3 protein U 0126 inhibits the reaction [Arecoline results in increased phosphorylation of MAPK3 protein]
[arecoline hydrobromide results in increased abundance of Arecoline] which results in increased expression of PHLPP2 mRNA; PHLPP2 protein affects the reaction [[arecoline hydrobromide results in increased abundance of Arecoline] which results in decreased phosphorylation of AKT1 protein]
Arecoline results in increased expression of PTGS2; Arecoline results in increased expression of PTGS2 mRNA [Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased expression of PTGS2 protein; Dinoprostone inhibits the reaction [helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased expression of PTGS2 protein]]; helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased expression of PTGS2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased expression of PTGS2 protein]]
[[Arecoline results in decreased expression of CDC25C] co-treated with [Arecoline results in increased expression of TP53]] results in decreased activity of CDK1 protein Arecoline results in increased expression of TP53 protein
CHRM1 gene results in increased susceptibility to xanomeline; CHRM1 results in increased susceptibility to xanomeline xanomeline binds to and results in increased activity of [CHRM1 protein binds to CHRM4 protein]
xanomeline binds to CHRM4 protein xanomeline binds to and results in increased activity of [CHRM1 protein binds to CHRM4 protein] [WIN 62577 co-treated with Quinuclidinyl Benzilate] inhibits the reaction [xanomeline binds to CHRM4 protein] CHRM4 gene results in increased susceptibility to xanomeline; CHRM4 results in increased susceptibility to xanomeline
browse the term
